On April 1, 2026, the FDA approved Foundayo, the brand name for orforglipron, for chronic weight management in adults with obesity and in adults with overweight who also have at least one weight-related medical condition. It is the first new molecular entity approved under the FDA’s National Priority Voucher program, and the agency says the decision came just 50 days after filing. [1]
The headline is simple: there is now an FDA-approved GLP-1 weight-loss pill that is not an injection. Foundayo is a once-daily tablet, and both the FDA and Lilly say it can be taken without the empty-stomach routine that makes oral semaglutide more finicky. [1] [2] [3]
That does not mean every current Ozempic, Wegovy, Mounjaro, or Zepbound user should suddenly switch. The convenience argument is real. The efficacy tradeoff is real too. So is the insurance question. This guide is the short version for people trying to decide what this approval changes in actual life.
If you need the broader background first, read our GLP-1 receptor agonist guide. If you are comparing current injectables, keep our Ozempic vs. Mounjaro breakdown and full GLP-1 side effects guide open too.
What exactly did the FDA approve?
Foundayo is approved with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:
- adults with obesity
- adults with overweight plus at least one weight-related comorbid condition
The FDA announcement does not say Foundayo is approved for type 2 diabetes. That matters. Someone taking Ozempic or Mounjaro mainly for glucose control should not assume this is an interchangeable on-label replacement. [1] [5]
The product is a GLP-1 receptor agonist in tablet form taken once daily. According to the FDA release, dosing starts at 0.8 mg, increases to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days, with optional further increases to 9 mg, 14.5 mg, or 17.2 mg based on response and tolerability. [1] [5]
Why people are paying attention: the practical difference is not subtle
Foundayo is not just “another GLP-1.” The practical selling point is obvious:
- it is a pill
- it is taken once daily
- it can be taken with or without food
- Lilly says there are no food or water restrictions
That makes it much simpler than oral semaglutide for day-to-day use. Lilly’s official patient page says Foundayo can be taken “on your schedule” and “without the hassle of food or water restrictions.” It also says to store it at room temperature and protect it from light by keeping it in the original bottle and carton. [3] [5]
If your biggest barrier to GLP-1 treatment has been injections, refrigeration anxiety, or the narrow dosing routine around some oral options, this approval matters.
The actual numbers: how much weight did people lose?
The most important obesity trial behind the approval is ATTAIN-1, published in the New England Journal of Medicine in 2025. This phase 3 trial randomized 3,127 adults with obesity without diabetes to daily oral orforglipron or placebo for 72 weeks. [6]
Here is what the trial found for mean weight change at week 72:
| Group | Mean body weight change |
|---|---|
| Placebo | -2.1% |
| Orforglipron 6 mg | -7.5% |
| Orforglipron 12 mg | -8.4% |
| Orforglipron 36 mg | -11.2% |
The highest-dose group also gives a cleaner picture of what “meaningful” looked like:
- 54.6% lost at least 10% of body weight
- 36.0% lost at least 15%
- 18.4% lost at least 20%
In the placebo group, those figures were 12.9%, 5.9%, and 2.8%. [6]
That is solid efficacy. It is not fake-news efficacy. It is real weight loss over a long trial.
How does Foundayo compare with the injectable GLP-1s?
This is the part where most news coverage gets sloppy.
There is no direct head-to-head obesity trial showing Foundayo versus Wegovy or Zepbound. So any injectable comparison right now is cross-trial, not proof.
Still, the cross-trial context matters:
- In ATTAIN-1, oral orforglipron reached 11.2% mean weight loss at 72 weeks on the highest dose. [6]
- In STEP 1, once-weekly semaglutide 2.4 mg reached 14.9% mean weight loss at 68 weeks. [8]
- In SURMOUNT-1, once-weekly tirzepatide 15 mg reached 20.9% mean weight loss at 72 weeks. [9]
That does not mean Foundayo is a weak drug. It means the current evidence suggests a tradeoff:
- Foundayo looks easier to take
- weekly injectables still look stronger on average for weight loss
If you hate injections, a daily pill with lower average weight loss may still be the better fit. If your main goal is maximum expected weight loss and you tolerate injections well, the weekly injectable options still look harder to beat.
What about side effects?
No surprise here: Foundayo looks like a GLP-1.
The FDA says Foundayo can cause nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, belching, reflux, gas, and hair loss. [1] [5]
The label is more useful than a vague “GI side effects are possible” sentence. In the pooled weight-management trials:
- gastrointestinal adverse reactions occurred in 60% of patients on the 5.5 mg dose
- 68% on the 9 mg dose
- 69% on the 17.2 mg dose
- versus 37% with placebo
More patients on Foundayo also stopped treatment because of GI side effects:
- 3% at 5.5 mg
- 6% at 9 mg
- 6% at 17.2 mg
- versus 0.7% with placebo [5]
That is the honest framing. Foundayo is a more convenient GLP-1, not a magically side-effect-free one.
If nausea, reflux, constipation, or vomiting have been the hardest part of GLP-1 treatment for you, read our full GLP-1 side effects guide before assuming the pill format will solve everything.
Is Foundayo available yet?
Yes, but rollout matters.
Lilly says:
- prescriptions are being accepted immediately
- LillyDirect shipping begins April 6, 2026
- broader U.S. retail pharmacy and telehealth availability should follow shortly after [2]
That means the answer to “Can I get it this week?” is probably different depending on where you fill prescriptions and whether your prescriber uses LillyDirect, retail pharmacy, or a telehealth platform.
How much will Foundayo cost?
This is where a lot of sites will overstate certainty. The official pages do not justify that.
What Lilly’s public pages say right now:
- self-pay starts at $149 per month for the 0.8 mg dose through LillyDirect
- eligible commercially insured patients may pay as little as $25 per month
Those are starting offers, not a full map of every real-world price patients will face across every dose and insurance design. [2] [4]
So the honest answer is:
- there is a verified low-entry self-pay offer
- there is a verified commercial-insurance savings offer
- we still do not know what average long-term out-of-pocket cost will look like once patients titrate up, hit plan restrictions, or move outside LillyDirect
Should current GLP-1 patients switch?
Usually not just because this exists.
If you are doing well on Wegovy or Zepbound for obesity
Foundayo may be more convenient, but the published cross-trial efficacy still looks lower than the best weekly injectable obesity data. Convenience alone may not be worth giving up stronger average weight-loss performance. [6] [8] [9]
If injections are the main reason you have avoided treatment
Foundayo is a much bigger deal. A once-daily pill without food or water restrictions removes a real barrier. That could expand access for people who have been unwilling to start an injectable or who have trouble sticking with one. [2] [3]
If you take Ozempic or Mounjaro for type 2 diabetes
Be more careful. Foundayo’s current approval is for chronic weight management, not type 2 diabetes treatment. Do not assume a straight switch makes clinical or insurance sense. [1] [5]
If side effects forced you off an injectable
Do not assume the oral route automatically fixes that. The label still shows a high GI side-effect burden, especially during dose escalation. [5]
What we still do not know
This matters as much as the approval itself.
Here is what is still missing or still too early to call:
- head-to-head obesity data against Wegovy or Zepbound
- real-world persistence, meaning how many patients stay on the daily pill after the first few months
- broad insurance behavior, especially after the initial launch offers
- how higher-dose self-pay pricing will look outside the entry offer
- whether many diabetes prescribers will wait for a separate diabetes approval before using the drug more broadly
There is also a practical unknown that will matter more than many readers realize: some people prefer a weekly shot over a daily pill because it is easier to remember. A daily tablet is more familiar, but it is also more frequent.
Bottom line
Foundayo is a real approval with real upside. The FDA approved it on April 1, 2026 for chronic weight management, and the clinical data show that oral orforglipron can produce meaningful long-term weight loss. [1] [6]
The biggest advantage is practical: it is a once-daily GLP-1 pill that can be taken without food or water restrictions. [2] [3]
The biggest catch is also practical: the weekly injectables still look stronger on average for weight loss, and the insurance story is not fully settled yet. [4] [8] [9]
If you want the most useful GLP-1 updates, not the soft-focus version, join the newsletter. That is where we send the approvals, pricing changes, and comparison tables worth screenshotting.
